Menarini
The Menarini Group is an Italian pharmaceutical company. Its headquarters is in Florence, Tuscany, and it has three divisions: Menarini Ricerche, Menarini Biotech, and Menarini Diagnostics. It develops pharmacological solutions for cardiovascular diseases, oncology, pain/inflammation, asthma and anti-infectives. Menarini's research activities are carried out through Menarini Ricerche, which deals with all R&D activities, from the creation of new projects to drug registration. Its Menarini Biotech follows the creation of a biotechnological drug from the very early stages of research, through to the pilot scale and up to industrial production. The Group's Menarini Diagnostics division is a healthcare company with a worldwide network of affiliates partners and distributors focused on diabetes, haematology, clinical chemistry, urinalysis, and immunology. In 2025, the company had 17,800 employees worldwide.
Beyond's analysis on Menarini
Recent news mentioning Menarini
- — Gan & Lee и Menarini Group сотрудничают для продвижения бофанглутида в Европе
- — Gan & Lee y Menarini Group se asocian para impulsar el desarrollo de bofanglutida en Europa
- — Gan & Lee a Menarini Group uzavřely partnerství k prosazení přípravku bofanglutid v Evropě
- — Gan & Lee und die Menarini Group schließen Partnerschaft zur Weiterentwicklung von Bofanglutide in Europa
- — Gan & Lee et le groupe Menarini s'associent pour faire progresser le bofanglutide en Europe
- — Gan & Lee i Menarini Group łączą siły na rzecz rozwoju bofanglutydu w Europie
- — Gan & Lee and Menarini Group Partner to Advance Bofanglutide in Europe
- — NewAmsterdam Pharma und die Menarini Group erhalten positive Stellungnahme des CHMP mit der Empfehlung zur Erteilung einer Zulassung für Ubeslo® (Obicetrapib-Monotherapie) und Evlarco® (Festsatzkombination aus Obicetrapib und Ezetimib)
- — NewAmsterdam Pharma et le groupe Menarini reçoivent un avis favorable du CHMP recommandant l'autorisation de mise sur le marché d'Ubeslo® (obicetrapib en monothérapie) et d'Evlarco® (association à dose fixe d'obicetrapib et d'ézétimibe)